Stoke Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | $8,780 | $12,405 |
| Operating expenses: | ||
| Research and development | 82,231 | 77,837 |
| General and administrative | 41,322 | 38,924 |
| Total operating expenses | 123,553 | 116,761 |
| Loss from operations | (114,773) | (104,356) |
| Other income (expense): | ||
| Interest income (expense), net | 9,908 | 3,122 |
| Other income (expense), net | 166 | 167 |
| Total other income (expense) | 10,074 | 3,289 |
| Net loss | $(104,699) | $(101,067) |
| Net loss per share—basic and diluted | $(2.38) | $(2.60) |
| Weighted average common shares outstanding—basic and diluted | 43,994,862 | 38,897,442 |
| Comprehensive loss: | ||
| Net loss | $(104,699) | $(101,067) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities | 1,151 | (1,007) |
| Total other comprehensive gain (loss) | $1,151 | $(1,007) |
| Comprehensive loss | $(103,548) | $(102,074) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.